Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this Post-Marketing Study is to monitor the safety of a novel
smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical
practice for 12 weeks among Filipino smokers.
The secondary objective is to further evaluate the effectiveness of Varenicline (Champix™) as
an aid in smoking cessation based on the 7-day point prevalence of smoking cessation